Entities / Company
Jazz Pharmaceuticals.
Irish tax-registered pharmaceutical corporation
- Reports this week
- 3
- Active events
- 3
- Connections
- 99
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Jazz Pharmaceuticals plans U.S. launch of Ziihera.Well supported5 reports
-
Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.Some support1 report
-
Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.Well supported4 reports
Earlier this month
-
The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.Some support1 report
-
Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.Some support4 reports
-
Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.Some support2 reports1 development inside
-
Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Some support1 report
One to three months ago
-
Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.Some support1 report
-
Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.Speculative3 reports2 developments inside
-
Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.Some support1 report
-
Analyst coverage and company performance data published regarding Jazz Pharmaceuticals, involving MarketBeat, Royal Bank of Canada, and TD Cowen.Some support1 report
-
Dr. Mark D. Smith holds a Clinical Professorship at UC San Francisco, serves on Jazz Pharmaceuticals boards, and was elected to the National Academy of Medicine in 2001.Some support1 report
-
Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.Some support5 reports
Gone quiet
No new reports in 90+ days-
Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.Well supported4 reports
-
Trump-era tariffs are benefiting certain AI stocks, with Jazz Pharmaceuticals noted as a beneficiary.Some support2 reports2 developments inside
-
Jazz Pharmaceuticals disclosed stock transactions via required filings with the SEC.Some support5 reports
-
FDA granted approval to Zepzelca in 2025, which was approved in partnership with Roche's Tecentriq.Some support1 report
-
A prostate cancer awareness campaign featuring Jazz Pharmaceuticals, George Kittle, and Delanie Walker took place in Cannes.Some support1 report
-
Morgan Stanley and Truist Financial have issued rating updates and price targets for Jazz Pharmaceuticals, requiring filings with the SEC.Some support1 report
-
Jazz Pharmaceuticals filed required documentation with the SEC regarding market transparency on June 11, 2026.Some support1 report
-
Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.Some support1 report
-
AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.Some support1 report
-
Jazz Pharmaceuticals received conditional marketing approval from the European Commission on July 1, 2025.Speculative1 report
-
Analyst questions were raised on August 13, 2025, regarding the sustainability of Xywav patient adds for Jazz Pharmaceuticals.Some support1 report
-
Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.Some support2 reports
-
Jazz Pharmaceuticals announced that Renee Gala was selected as the new CEO of the company on July 10, 2025. Bruce Cozadd previously held the CEO role.Some support1 report
-
Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.Some support2 reports
-
Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.Some support1 report
-
UBS reiterated a Buy rating on Jazz Pharmaceuticals on July 2, 2025.Speculative1 report
-
Jazz Pharmaceuticals, headquartered in Dublin, Ireland, participated in the Wells Fargo Healthcare Conference.Some support5 reports
-
Jazz Pharmaceuticals relocated its headquarters to Ireland while an aggressive tariff plan caused markets to tank.Some support5 reports
-
Jazz Pharmaceuticals is facing inquiries from Bank of America regarding tariff risks and company matters.Speculative1 report
-
Seamus Mulligan bought shares of Jazz Pharmaceuticals on July 2, 2025.Speculative1 report
-
Thierry orchestrated the acquisition of Amolyt Pharma by AstraZeneca and the acquisition of his venture Alizé Pharma 2 by Jazz Pharmaceuticals.Speculative1 report
-
Jazz Pharmaceuticals stock declined 11% on July 8, 2025, while the S&P 500 saw a gain of 5.3%.Speculative1 report
-
Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.Some support1 report
-
Benjamin Graham's investment philosophy is noted as guiding stock analysis for Jazz Pharmaceuticals.Some support1 report
-
Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.Some support2 reports
-
Jazz seeks Priority Review from FDA and announces results from Dublin.Some support1 report
-
Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.Some support1 report
-
Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.Well supported5 reports
-
Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
Around Jazz Pharmaceuticals this week
News at the entities that move Jazz Pharmaceuticals most-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Jazz Pharmaceuticals
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Jazz Pharmaceuticals
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Jazz Pharmaceuticals
-
Zymeworks StructuralZymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Moves Jazz Pharmaceuticals
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Jazz Pharmaceuticals
-
Ireland StructuralIreland is working to improve governmental transparency by enhancing its digital services.Moves Jazz Pharmaceuticals
Connections
The 30 strongest of 99, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Zymeworks Structural
A strategic partnership exists where Jazz utilizes Zymeworks' technology platform, with financial milestones and royalties tied to A's regulatory successes.
-
Chimerix (United States) Structural
Jazz Pharmaceuticals acquired Chimerix, establishing it as a subsidiary and gaining control over its assets.
-
FDA Structural
The FDA acts as the primary regulatory body, granting or denying market access and approvals for Jazz Pharmaceuticals' therapies and products.
-
SEC Structural
Jazz Pharmaceuticals must file disclosures and transactions with the SEC as required by market transparency regulations.
-
Nasdaq Structural
Jazz Pharmaceuticals is listed on the Nasdaq stock exchange.
-
Ireland Structural
Jazz Pharmaceuticals is headquartered in Ireland, a status established following a tax inversion merger in 2012.
-
AbCellera Operational
The companies maintain an active partnership focused on joint collaboration and development of multispecific antibodies.
-
Morgan Stanley Operational
Morgan Stanley provides investment ratings and price targets for Jazz Pharmaceuticals, influencing market perception.
Show all 30 connections
-
Johnson & Johnson Operational
The two companies are major pharmaceutical players who operate in the same competitive market space.
-
Elanco Operational
The two companies actively compete and operate within the specialized pharmaceutical market segment.
-
Securities and Exchange Commission Structural
Jazz Pharmaceuticals is subject to the filing and disclosure requirements of the U.S. Securities and Exchange Commission, including the 13F rule.
-
Mark D. Smith Structural
Mark D. Smith serves as a board member for Jazz Pharmaceuticals.
-
Food and Drug Administration Structural
Jazz Pharmaceuticals' market function is structurally dependent on regulatory approvals granted by the Food and Drug Administration.
-
Needham & Company Mentioned together
Needham & Company provides financial analysis and price target recommendations for Jazz Pharmaceuticals stock.
-
Bank of America Mentioned together
BoA conducts market research on Jazz Pharmaceuticals, including monitoring operational risks and issuing price targets.
-
Benzinga Mentioned together
Benzinga provides financial news coverage regarding Jazz Pharmaceuticals' earnings.
-
MarketBeat Mentioned together
MarketBeat tracks and reports on company performance data and analyst ratings for Jazz Pharmaceuticals.
-
Norway Shared context
Jazz Pharmaceuticals operates in Norway, evidenced by the regulatory approval of Ziihera.
-
Leerink partners Mentioned together
Leerink partners provided a price target update regarding Jazz Pharmaceuticals.
-
Cannes Shared context
The company's program was held in Cannes and demonstrated measurable healthcare impact.
-
Eli Lilly and Company Operational
Jazz Pharmaceuticals and Eli Lilly are active competitors within the major pharmaceutical stock market.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada analysts provide financial coverage and price objective raises for Jazz Pharmaceuticals.
-
Zoetis Operational
Market analysis compares the business strengths and financial performance of Jazz Pharmaceuticals and Zoetis.
-
TD Cowen Mentioned together
TD Cowen tracks Jazz Pharmaceuticals, evidenced by the firm upping its price objective.
-
Truist Financial Mentioned together
Truist Financial provided a buy rating and price objective for Jazz Pharmaceuticals.
-
Liechtenstein Shared context
Jazz Pharmaceuticals operates within the pharmaceutical market context of Liechtenstein.
-
PharmaMar Transactional
The relationship involved a specific, time-bound partnership where the Phase 3 clinical trial for Jazz's drug was conducted.
-
Hoffmann-La Roche Transactional
A drug (Zepzelca) was approved in the market alongside a Roche product (Tecentriq).
-
Deutsche Bank Operational
Jazz Pharmaceuticals engaged with a Deutsche Bank analyst to discuss its development plans.
-
Buy Mentioned together
No evidence was found linking Jazz Pharmaceuticals and Buy.
History
Events by the month they beganSeptember 2026
4 events- Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.
August 2026
7 events- Jazz Pharmaceuticals plans U.S. launch of Ziihera.
- Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.
- Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.
- Analyst coverage and company performance data published regarding Jazz Pharmaceuticals, involving MarketBeat, Royal Bank of Canada, and TD Cowen.
- Dr. Mark D. Smith holds a Clinical Professorship at UC San Francisco, serves on Jazz Pharmaceuticals boards, and was elected to the National Academy of Medicine in 2001.
June 2026
31 events- Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.
- Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.
- Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.
- Trump-era tariffs are benefiting certain AI stocks, with Jazz Pharmaceuticals noted as a beneficiary.
- Jazz Pharmaceuticals disclosed stock transactions via required filings with the SEC.
- FDA granted approval to Zepzelca in 2025, which was approved in partnership with Roche's Tecentriq.
- A prostate cancer awareness campaign featuring Jazz Pharmaceuticals, George Kittle, and Delanie Walker took place in Cannes.
- Morgan Stanley and Truist Financial have issued rating updates and price targets for Jazz Pharmaceuticals, requiring filings with the SEC.
- Jazz Pharmaceuticals filed required documentation with the SEC regarding market transparency on June 11, 2026.
- Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.
- AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.
- Jazz Pharmaceuticals received conditional marketing approval from the European Commission on July 1, 2025.
- Analyst questions were raised on August 13, 2025, regarding the sustainability of Xywav patient adds for Jazz Pharmaceuticals.
- Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.
- Jazz Pharmaceuticals announced that Renee Gala was selected as the new CEO of the company on July 10, 2025. Bruce Cozadd previously held the CEO role.
- Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.
- Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.
- UBS reiterated a Buy rating on Jazz Pharmaceuticals on July 2, 2025.
- Jazz Pharmaceuticals, headquartered in Dublin, Ireland, participated in the Wells Fargo Healthcare Conference.
- Jazz Pharmaceuticals relocated its headquarters to Ireland while an aggressive tariff plan caused markets to tank.
- Jazz Pharmaceuticals is facing inquiries from Bank of America regarding tariff risks and company matters.
- Seamus Mulligan bought shares of Jazz Pharmaceuticals on July 2, 2025.
- Thierry orchestrated the acquisition of Amolyt Pharma by AstraZeneca and the acquisition of his venture Alizé Pharma 2 by Jazz Pharmaceuticals.
- Jazz Pharmaceuticals stock declined 11% on July 8, 2025, while the S&P 500 saw a gain of 5.3%.
- Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
- Benjamin Graham's investment philosophy is noted as guiding stock analysis for Jazz Pharmaceuticals.
- Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.
- Jazz seeks Priority Review from FDA and announces results from Dublin.
- Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.
- Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.
- Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.